Serono Sues Cell Genesys Over TKT Gene Activation Patent
A subsidiary of Switzerland's Serono has sued Transkaryotic Therapies (TKT) licensee Cell Genesys, alleging that gene activation technology used in the production of TKT's biological drugs infringes a U.S. patent....To view the full article, register now.
Already a subscriber? Click here to view full article